Blood Test ‘Clock’ Predicts Alzheimer’s Symptom Onset Within Years
Washington University researchers have developed a blood test using p-tau217 protein levels to predict Alzheimer’s symptom onset within three to four years.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Plasma pTau Shows Promise as Early Endpoint in Alzheimer’s Trials
New cross-trial analysis supports the biomarker's potential to predict clinical benefit, reinforcing biomarker-driven trial designs.
Dementias & Alzheimer’s
Latest
Labcorp to Offer FDA-Cleared Blood Test for Alzheimer’s Assessment in Primary Care
The Elecsys pTau181 test measures phosphorylated Tau 181 protein to help rule out Alzheimer's-related amyloid pathology in patients 55 and older.
pTau217 Antibody Demonstrates Reliability for Alzheimer’s Detection
ALZpath pTau217 antibody data was included in 37 submissions at AAIC, building on research demonstrating its sensitivity and accuracy in blood-based tests for Alzheimer’s disease.
Read More
Blood-Based Biomarker Testing for Alzheimer’s Gets Formal Guidance
The Alzheimer’s Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Read More
AI-Enhanced EEG Promises Early Alzheimer’s Detection
AI-enhanced EEG technology is emerging as a promising tool for early detection of Alzheimer’s disease, potentially facilitating prevention efforts before symptoms appear.
Read More
Roche Shares Alzheimer’s Drug and Diagnostic Advances at AAIC 2025
At the Alzheimer’s Association International Conference, Roche shared new data on its investigational antibody trontinemab and its Elecsys pTau217 blood test.
Read More
Blood-Based Biomarkers Are Advancing Alzheimer’s Testing
Blood-based biomarker tests are revolutionizing Alzheimer’s diagnostic testing and management of Alzheimer’s disease.
Read More
Alzheimer’s Biomarkers Can Be Detected as Early as Middle Age
A Finnish study reveals that Alzheimer’s-related blood biomarkers can be detected in middle age, potentially spotting the disease sooner.
Read More
Are AI-Powered Neurodiagnostic Solutions the New Frontier in Alzheimer’s Prevention?
AI-enhanced EEG technology offers a promising, accessible way to detect early signs of Alzheimer’s disease—years before symptoms appear.
Read More
Quest Diagnostics to Offer Fujirebio Blood Test for Alzheimer’s
Quest Diagnostics will offer a Fujirebio blood test this summer to enhance early detection of Alzheimer’s disease.
Read More
Simoa Technology Platform Expands Into New Market
Quanterix Corporation’s HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration in South Korea.
Read More
Blood Test for Alzheimer’s Cleared by FDA
An FDA-cleared blood test that measures key Alzheimer’s disease biomarkers is a less invasive, more accurate method to diagnose the condition.
Read More
Test Detects P-SYN in Skin Biopsies of Patients with iRBD
Summary: CND Life Sciences has released baseline results from its NIH-funded Syn-Sleep Study,...
Read More
NULISAseq CNS Disease Panel 120 Expanded with Blood-Based Brain-Derived pTau Assays
Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 to include highly sensitive, blood-based assays.
Read More
Astrocytes Play Key Role in Alzheimer’s Disease
Researchers have identified the key enzyme causing Alzheimer’s disease by linking it to excessive GABA production in reactive astrocytes.
Read More
Blood Test Provides Accurate Results for Alzheimer’s Detection
A large international study found that a simpler blood test method using plasma P-tau217 can accurately detect Alzheimer’s disease.
Read More
Parkinson’s Disease Needs Improved Diagnostic Processes
A study found that up to 17.7% of initial Parkinson’s disease diagnoses are later revised, highlighting the challenges of its diagnosis.
Read More